RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2024.
“Our business is demonstrating strong momentum as we exit the first half of the year,” said Robert M. Davis, chairman and chief executive officer, Merck. “Through excellent scientific, commercial and operational execution, we’re achieving significant milestones for our company and for patients, including the launch of WINREVAIR. I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as we continue delivering innovation that solves unmet medical needs.”
Financial Summary
|
$ in millions, except EPS amounts |
Second Quarter |
|||
|
2024 |
2023 |
Change |
Change Ex- |
|
|
Sales |
$16,112 |
$15,035 |
7% |
11% |
|
GAAP net income (loss)1 |
5,455 |
(5,975) |
N/M |
N/M |
|
Non-GAAP net income (loss) that excludes certain items1,2* |
5,809 |
(5,220) |
N/M |
N/M |
|
GAAP EPS |
2.14 |
(2.35) |
N/M |
N/M |
|
Non-GAAP EPS that excludes certain items2* |
2.28 |
(2.06) |
N/M |
N/M |
|
*Refer to table on page 7. |
||||
|
N/M – Not meaningful |
||||
For the second quarter of 2024, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.14 and non-GAAP EPS was $2.28. GAAP and non-GAAP loss per share for the second quarter of 2023 include a charge of $4.02 per share for the acquisition of Prometheus Biosciences, Inc. (Prometheus). Non-GAAP EPS in both periods excludes acquisition- and divestiture-related costs, costs related to restructuring programs, as well as income and losses from investments in equity securities. Non-GAAP EPS in the second quarter of 2024 also excludes a tax benefit due to a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
Year-to-date results can be found in the attached tables.
Second-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant performance drivers.
|
|
Second Quarter |
||||
|
$ in millions |
2024 |
2023 |
Change |
Change Ex-Exchange |
Commentary |
|
Total Sales |
$16,112 |
$15,035 |
7% |
11% |
Approximately 2 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. |
|
Pharmaceutical |
14,408 |
13,457 |
7% |
11% |
Increase driven by growth in oncology, cardiovascular and vaccines, partially offset by declines in diabetes and virology. |
|
KEYTRUDA |
7,270 |
6,271 |
16% |
21% |
Growth driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer (TNBC) and renal cell carcinoma, as well as non-small cell lung cancer in the U.S., and continued strong global demand from metastatic indications. Approximately 4 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. |
|
GARDASIL/GARDASIL 9 |
2,478 |
2,458 |
1% |
4% |
Growth primarily due to higher sales in the U.S. driven by higher pricing, demand and public-sector buying patterns, as well as higher demand in certain ex-U.S. markets. Growth was largely offset by lower sales in China due to timing of shipments compared with prior year. |
|
JANUVIA/JANUMET |
629 |
864 |
-27% |
-23% |
Decline primarily due to lower pricing and demand in the U.S., as well as ongoing generic competition in many international markets, particularly in Europe and the Asia Pacific region. |
|
PROQUAD, M-M-R II and VARIVAX |
617 |
582 |
6% |
7% |
Growth largely from higher pricing and demand in the U.S. |
|
BRIDION |
455 |
502 |
-9% |
-8% |
Decline primarily due to generic competition in certain ex-U.S. markets, particularly in Europe and the Asia Pacific region, partially offset by higher demand in the U.S. |
|
Lynparza* |
317 |
310 |
2% |
4% |
Growth due to higher demand in the U.S. and certain international markets, particularly in China and Europe. |
|
Lenvima* |
249 |
242 |
3% |
4% |
Growth primarily from higher demand in the U.S. |
|
VAXNEUVANCE |
189 |
168 |
13% |
16% |
Growth largely driven by continued uptake from launches in Japan and Europe, partially offset by lower demand and public-sector buying patterns in the U.S. |
|
PREVYMIS |
188 |
143 |
31% |
35% |
Growth primarily due to higher global demand, particularly in the U.S., China and Europe. |
|
ROTATEQ |
163 |
131 |
25% |
26% |
Growth primarily due to timing of shipments to China and public-sector buying patterns in the U.S., partially offset by lower demand in the U.S. |
|
WELIREG |
126 |
50 |
150% |
150% |
Growth primarily driven by higher demand in the U.S., largely attributable to launch of a new indication. |
|
LAGEVRIO |
110 |
203 |
-46% |
-42% |
Decline due to lower demand and pricing in certain markets in the Asia Pacific region, partially offset by higher demand in Japan and the U.S. |
|
WINREVAIR |
70 |
– |
– |
– |
Represents sales in the U.S. following approval in March 2024. About 40% of sales were attributable to doses administered to patients and remainder was due to distributors building inventory in support of increasing demand. |
|
Animal Health |
1,482 |
1,456 |
2% |
6% |
Growth primarily driven by higher pricing in both Livestock and Companion Animal product portfolios, as well as higher demand for Livestock products, partially offset by a decline in Companion Animal distributor inventory. Approximately 3 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. |
|
Livestock |
837 |
807 |
4% |
11% |
Growth primarily driven by higher demand for ruminant and poultry products, as well as higher pricing across product portfolio. |
|
Companion Animal |
645 |
649 |
-1% |
1% |
Sales were relatively flat compared with prior year reflecting lower distributor inventory, largely offset by higher pricing across product portfolio. Sales of BRAVECTO were $331 million and $326 million in current and prior-year quarters, respectively, which represented growth of 2%, or 3% excluding impact of foreign exchange. |
|
Other Revenues** |
222 |
122 |
82% |
53% |
Growth primarily due to higher royalty income and favorable impact of revenue hedging activities. |
|
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. |
|||||
|
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue hedging activities. |
|||||
Second-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
|
$ in millions |
GAAP |
Acquisition- |
Restructuring |
(Income) |
Non- |
|
Second Quarter 2024 |
|||||
|
Cost of sales |
$3,745 |
$606 |
$66 |
$- |
$3,073 |
|
Selling, general and administrative |
2,739 |
24 |
31 |
– |
2,684 |
|
Research and development |
3,500 |
20 |
– |
– |
3,480 |
|
Restructuring costs |
80 |
– |
80 |
– |
– |
|
Other (income) expense, net |
42 |
(17) |
– |
(49) |
108 |
|
|
|
|
|
|
|
|
Second Quarter 2023 |
|
|
|
|
|
|
Cost of sales |
$4,024 |
$467 |
$32 |
$- |
$3,525 |
|
Selling, general and administrative |
2,702 |
25 |
52 |
– |
2,625 |
|
Research and development |
13,321 |
9 |
1 |
– |
13,311 |
|
Restructuring costs |
151 |
– |
151 |
– |
– |
|
Other (income) expense, net |
172 |
(3) |
– |
194 |
(19) |
GAAP Expense, EPS and Related Information
Gross margin was 76.8% for the second quarter of 2024 compared with 73.2% for the second quarter of 2023. The increase was primarily due to the favorable impact of product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), partially offset by higher amortization of intangible assets.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the second quarter of 2024, an increase of 1% compared with the second quarter of 2023. The increase was primarily due to higher administrative and promotional costs, largely offset by the favorable impact of foreign exchange and lower restructuring costs.
Research and development (R&D) expenses were $3.5 billion in the second quarter of 2024 compared with $13.3 billion in the second quarter of 2023. The decrease was primarily due to a $10.2 billion charge in the second quarter of 2023 for the acquisition of Prometheus, partially offset by higher clinical development spending and increased compensation and benefit costs.
Other (income) expense, net, was $42 million of expense in the second quarter of 2024 compared with $172 million of expense in the second quarter of 2023. The decrease was primarily due to income from investments in equity securities in 2024 compared with losses in 2023, partially offset by higher net interest expense in 2024.
The effective tax rate of 9.1% for the second quarter of 2024 includes a 4.3 percentage point favorable impact due to a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
GAAP EPS was $2.14 for the second quarter of 2024 compared with GAAP loss per share of $2.35 for the second quarter of 2023. GAAP loss per share in the second quarter of 2023 includes a charge of $4.02 per share for the acquisition of Prometheus.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 80.9% for the second quarter of 2024 compared with 76.6% for the second quarter of 2023. The increase was primarily due to the favorable impact of product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9).
Non-GAAP SG&A expenses were $2.7 billion in the second quarter of 2024, an increase of 2% compared with the second quarter of 2023. The increase was primarily due to higher administrative and promotional costs, largely offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $3.5 billion in the second quarter of 2024 compared with $13.3 billion in the second quarter of 2023. The decrease was primarily due to a $10.2 billion charge in the second quarter of 2023 for the acquisition of Prometheus, partially offset by higher clinical development spending and increased compensation and benefit costs.
Non-GAAP other (income) expense, net, was $108 million of expense in the second quarter of 2024 compared with $19 million of income in the second quarter of 2023, primarily due to higher net interest expense.
The non-GAAP effective tax rate was 14.1% for the second quarter of 2024.
Non-GAAP EPS was $2.28 for the second quarter of 2024 compared with non-GAAP loss per share of $2.06 for the second quarter of 2023. Non-GAAP loss per share in the second quarter of 2023 includes a charge of $4.02 per share for the acquisition of Prometheus.
A reconciliation of GAAP to non-GAAP net income (loss) and EPS is provided in the table that follows.
|
Second Quarter |
||
|
$ in millions, except EPS amounts |
2024 |
2023 |
|
EPS |
|
|
|
GAAP EPS |
$2.14 |
$(2.35) |
|
Difference |
0.14 |
0.29 |
|
Non-GAAP EPS that excludes items listed below2 |
$2.28 |
$(2.06) |
|
|
|
|
|
Net Income (Loss) |
|
|
|
GAAP net income (loss)1 |
$5,455 |
$(5,975) |
|
Difference |
354 |
755 |
|
Non-GAAP net income (loss) that excludes items listed below1,2 |
$5,809 |
$(5,220) |
|
|
|
|
|
Excluded Items: |
|
|
|
Acquisition- and divestiture-related costs3 |
$633 |
$498 |
|
Restructuring costs |
177 |
236 |
|
(Income) loss from investments in equity securities |
(49) |
194 |
|
Decrease to net income/increase to net loss before taxes |
761 |
928 |
|
Income tax (benefit) expense4 |
(407) |
(173) |
|
Decrease to net income/increase to net loss |
$354 |
$755 |
Pipeline and Portfolio Highlights
In the second quarter, Merck demonstrated further progress in its strong and diverse pipeline, achieving multiple regulatory and clinical milestones.
In vaccines, Merck recently received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, now the first pneumococcal conjugate vaccine specifically designed to address the serotypes responsible for approximately 85% of invasive pneumococcal disease cases in adults age 65 and older, based on the U.S. Centers for Disease Control and Prevention (CDC) data from 2018-2021. The CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend CAPVAXIVE for adults age 65 and older who have not received a pneumococcal conjugate vaccine or whose vaccination history is unknown, for adults 19 to 64 with certain risk conditions, and for adults 19 and older who have started their pneumococcal vaccine series with PCV13. Additionally, shared clinical decision-making is recommended for a supplemental dose of CAPVAXIVE for adults over 65 who completed their vaccine series with both PCV13 and PPSV23.
The company also recently announced positive topline results from its Phase 2b/3 trial of clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative monoclonal antibody for infants, which met all primary safety and efficacy endpoints.
In cardiometabolic disease, Merck continued to make progress in its launch of WINREVAIR in the U.S. As of the end of June, more than 1,000 patients have received WINREVAIR. The company also announced that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for WINREVAIR. If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to be approved in Europe, offering a new treatment option for certain adults with this rare, progressive disease. Additional worldwide regulatory filings for WINREVAIR are underway.
In oncology, Merck received FDA approval for KEYTRUDA in combination with chemotherapy, followed by KEYTRUDA as a single agent, for the treatment of certain patients with endometrial carcinoma. This marks the 40th indication for KEYTRUDA in the U.S., reinforcing its importance as a foundational therapy for certain types of cancer.
At the 2024 American Society of Clinical Oncology Annual Meeting, new data were presented on four approved oncology medicines and four pipeline candidates in more than 25 types of cancer. In collaboration with Moderna, Inc., Merck announced encouraging three-year follow-up data for V940 (mRNA-4157) in combination with KEYTRUDA for the adjuvant treatment of patients with high-risk stage III and IV melanoma following complete resection. In addition, new Phase 3 data from a study conducted in China and independently led by Kelun-Biotech evaluating sacituzumab tirumotecan (MK-2870/SKB264), an investigational anti-TROP2 antibody-drug conjugate being developed by Merck in collaboration with Kelun-Biotech, were presented in previously treated patients with locally recurrent or metastatic TNBC.
Merck Animal Health launched the 12-month injectable formulation of BRAVECTO for use in dogs in a number of markets in Europe for the treatment and persistent killing of fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, Ixodes hexagonus, and Dermacentor reticulatus). In addition, in July 2024, Merck completed the acquisition of the aqua business of Elanco Animal Health Incorporated.
In July 2024, Merck also completed the acquisition of Eyebiotech Limited (EyeBio), which includes the lead candidate Restoret™/MK-3000 that is being evaluated for the treatment of patients with certain retinal diseases, including diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates. And, Merck and Orion Corporation announced the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates, into an exclusive global license for Merck.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table that follows.
|
Oncology |
FDA Approved KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma, Based on Results From Phase 3 NRG-GY018/KEYNOTE-868 Trial |
|
|
FDA Granted Priority Review to Merck’s Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma, Based on Results From Phase 3 KEYNOTE-483 Trial; FDA Set Prescription Drug User Fee Act (PDUFA) Date of Sept. 25, 2024 |
||
|
Merck Received Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma, Based on Results From Phase 3 KEYNOTE-A39/EV-302 Trial |
||
|
Moderna and Merck Announced Three-Year Data for mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated Sustained Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection |
||
|
Merck Announced Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage TNBC |
||
|
Merck Announced Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
||
|
Patritumab Deruxtecan Biologics License Application Submission Received Complete Response Letter From FDA Due to Inspection Findings at Third-Party Manufacturer |
||
|
Vaccines |
FDA Approved CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults, Based on Results From Four Phase 3 Trials |
|
|
CDC’s ACIP Unanimously Recommended CAPVAXIVE for Pneumococcal Vaccination in Appropriate Adults |
||
|
Merck Announced Topline Results From Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants, Met All Primary Safety and Efficacy Endpoints |
||
|
Cardiometabolic |
Merck Received Positive EU CHMP Opinion for WINREVAIR (sotatercept) in PAH |
Full-Year 2024 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
|
|
Full Year 2024 |
|
|
|
Updated |
Prior |
|
Sales* |
$63.4 to $64.4 billion |
$63.1 to $64.3 billion |
|
Non-GAAP Gross margin2 |
Approximately 81% |
Approximately 81% |
|
Non-GAAP Operating expenses2** |
$26.8 to $27.6 billion |
$25.2 to $26.1 billion |
|
Non-GAAP Other (income) expense, net2 |
Approximately $350 million expense |
Approximately $250 million expense |
|
Non-GAAP Effective tax rate2 |
15.5% to 16.5% |
14.5% to 15.5% |
|
Non-GAAP EPS2*** |
$7.94 to $8.04 |
$8.53 to $8.65 |
|
Share count (assuming dilution) |
Approximately 2.54 billion |
Approximately 2.55 billion |
|
*The company does not have any non-GAAP adjustments to sales. |
||
|
**Includes one-time R&D charges of $656 million for Harpoon Therapeutics, Inc. (Harpoon) acquisition and $1.3 billion for EyeBio acquisition. Outlook does not assume any additional significant potential business development transactions. |
||
|
***Includes one-time charges totaling $0.77 per share for the Harpoon and EyeBio acquisitions. |
||
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation, including intangible asset impairment charges, legal settlements, and gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast and could have a significant impact on the company’s future GAAP results.
Merck continues to experience strong global demand for key growth products, particularly in oncology, and despite impacts related to the lower sell out of GARDASIL from Zhifei Biological Products Co., Ltd. (the company’s distributor and commercialization partner in China) into the points of vaccination in the market during the quarter, Merck is raising and narrowing its full-year sales outlook.
Merck now expects its full-year sales to be between $63.4 billion and $64.4 billion, including a negative impact of foreign exchange of approximately 3 percentage points, at mid-July 2024 exchange rates. Approximately 2 percentage points of the negative impact of foreign exchange is due to the devaluation of the Argentine peso, which the company expects will largely be offset by inflation-related price increases, consistent with practice in that market.
Merck now expects its full-year non-GAAP effective income tax rate to be between 15.5% and 16.5%, which includes an unfavorable impact related to the one-time charge for the acquisition of EyeBio, which is not tax deductible.
Merck now expects its full-year non-GAAP EPS to be between $7.94 and $8.04, including one-time charges of $0.26 and $0.51 per share for the acquisitions of Harpoon and EyeBio, respectively. The outlook includes a negative impact of foreign exchange of more than $0.30 per share. The negative impact of foreign exchange is primarily due to the devaluation of the Argentine peso, which the company expects will largely be offset by inflation-related price increases, consistent with practice in that market. This revised non-GAAP EPS range reflects the following items, which were not previously included in the outlook:
- A charge of $1.3 billion, or $0.51 per share, for the acquisition of EyeBio.
- Estimated 2024 expense of approximately $0.09 per share to be incurred to finance the EyeBio and Elanco aqua business acquisitions and to advance the acquired assets.
Consistent with past practice, the financial outlook does not assume additional significant potential business development transactions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to restructuring programs, income and losses from investments in equity securities, as well as a tax benefit in 2024 due to a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
